Skip to main content

Branded

  • Teva acquires Labrys in a deal that could reach $825 million

    JERUSALEM – Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.

  • Mission Pharmacal begins promotion of Elestrin

    SAN ANTONIO — Mission Pharmacal on Thursday announced that it has begun the promotion of Elestrin (estradiol gel) 0.06% in the United States through an agreement with Meda AB. The drug is a used as a topical hormone replacement gel to help treat hot flashes caused by menopause.

    The addition of Elestrin both complements and expands Mission Pharmacal's existing line of products for women, which includes such products as prescription prenatal vitamins, a bone health product, anti-infectives, an iron supplement and a urinary analgesic.

  • High blood pressure drugs may be associated with increased risk of vision-threatening disease

    SAN FRANCISCO — There may be a connection between taking vasodilators and developing early-stage, age-related macular degeneration, the leading cause of vision loss and blindness among Americans who are ages 65 and older, according to a study published online Wednesday in Ophthalmology, the journal of the American Academy of Ophthalmology.

  • FDA approves Trimel Pharmaceuticals' Natesto testosterone nasal gel

    TORONTO — Trimel Pharmaceuticals on Wednesday announced that the Food and Drug Administration has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. 

    Natesto is self-administered via a nasal applicator, thereby minimizing the risk of secondary exposure to testosterone of women or children.

  • Chronic pain sufferers advocate against stigma of prescription pain meds

  • FDA accepts NDA for investigational extended-release oral formulation of hydrocodone/APAP

    NEWARK, Calif. — Depomed on Wednesday announced that the Food and Drug Administration has accepted for filing a new drug application from Mallinckrodt for MNK-155. MNK-155 is an investigational, extended-release oral formulation of hydrocodone and acetaminophen that has been studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate.  MNK-155 is formulated with Depomed's Acuform drug delivery technology. 

  • Pfizer reiterates $118 billion bid for AstraZeneca was final offer

    NEW YORK — Pfizer on Monday reiterated that its bid on May 18 of $118 billion for AstraZeneca was the final offer on the table. 

    Following the AstraZeneca board's rejection of the proposal, Pfizer announced that it does not intend to make an offer for AstraZeneca.

  • JAMA: Antibiotic prescribing rate for acute bronchitis at 70% when it should be zero

    CHICAGO — Despite clear evidence of ineffectiveness, guidelines and more than 15 years of educational efforts stating that the antibiotic prescribing rate for acute bronchitis should be zero, the rate was about 70% from 1996 to 2010 and increased during this time period, according to a study in the May 21 issue of JAMA.

X
This ad will auto-close in 10 seconds